ORIC Pharmaceuticals Announced Initial Phase 1 Dose Escalation Data Of ORIC-114 In Patients With EGFR And HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile
Portfolio Pulse from Charles Gross
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced initial data from the ongoing ORIC-114 Phase 1 dose escalation trial for patients with EGFR or HER2 exon 20 mutated non-small cell lung cancer. The data shows CNS activity at multiple dose levels, systemic responses in heavily pre-treated NSCLC patients, and a favorable safety profile. The company believes this demonstrates a potential best-in-class profile for ORIC-114.
October 21, 2023 | 1:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The announcement of promising initial data from ORIC's Phase 1 trial could potentially boost investor confidence and positively impact the company's stock price in the short term.
Positive clinical trial results often lead to increased investor confidence as they indicate progress and potential future revenue streams. This news could therefore lead to a short-term increase in ORIC's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100